livevol_ophir
ET Sponsor
The company has traded 3600 options today on daily average option volume of 295. Zero (0) puts have traded today - everything has been a call.
The day's biggest trades tell the story. There is a buyer of both Aug 7.5 and Aug 10 calls. This is referred to as a call "stupid" (a spread that is the same side twice). Note the small OI relative to trade size - these are opening orders.
The Aug 7.5 calls are trading ~3.60 and the Aug 10 calls are trading ~1.85. I believe the 7's to be purchases because the biggest order was 1261 for 3.60 vs 3.30 x 3.70 NBBO. This is clearly closer to the offer - probably cust purchases (similar analysis for the Aug 10s).
What's the News? (below provided by www.theflyonthewall.com)
Enzon opens Phase 2 study of PEG-SN38 for breast cancer
Enzon Pharmaceuticals announced that the first patient has been treated in the Phase 2 studies of PEG-SN38 for metastatic breast cancer. PEG-SN38 or EZN-2208 is Enzonâs PEGylated form of SN38, the active metabolite of the cancer drug Camptosar. The PEG-SN38 compound is currently being evaluated in a Phase 2 study for metastatic colorectal cancer.
Regardless of the stock and trading - I hope this one turns out to be a winner.
You can see details, trades, price on my blog:
http://livevol.blogspot.com/2010/01/enzon-enzn-opening-call-stupid-purchase.html
The day's biggest trades tell the story. There is a buyer of both Aug 7.5 and Aug 10 calls. This is referred to as a call "stupid" (a spread that is the same side twice). Note the small OI relative to trade size - these are opening orders.
The Aug 7.5 calls are trading ~3.60 and the Aug 10 calls are trading ~1.85. I believe the 7's to be purchases because the biggest order was 1261 for 3.60 vs 3.30 x 3.70 NBBO. This is clearly closer to the offer - probably cust purchases (similar analysis for the Aug 10s).
What's the News? (below provided by www.theflyonthewall.com)
Enzon opens Phase 2 study of PEG-SN38 for breast cancer
Enzon Pharmaceuticals announced that the first patient has been treated in the Phase 2 studies of PEG-SN38 for metastatic breast cancer. PEG-SN38 or EZN-2208 is Enzonâs PEGylated form of SN38, the active metabolite of the cancer drug Camptosar. The PEG-SN38 compound is currently being evaluated in a Phase 2 study for metastatic colorectal cancer.
Regardless of the stock and trading - I hope this one turns out to be a winner.
You can see details, trades, price on my blog:
http://livevol.blogspot.com/2010/01/enzon-enzn-opening-call-stupid-purchase.html